Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus

Published:2016-03 Issue:3 Volume:38 Page:516-530
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Addy Carol,Tatosian Daniel,Glasgow Xiaoli S.,Gendrano Isaias N.,Kauh Eunkyung,Martucci Ashley,Johnson-Levonas Amy O.,Selverian Diana,Matthews Catherine Z.,Gutierrez Marie^ORCID,Wagner John A.,Aubrey Stoch S.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference27 articles.

1. Minireview: update on incretin biology: focus on glucagon-like peptide-1;Brubaker;Endocrinol,2010

2. The incretin system and its role in type 2 diabetes mellitus;Holst;Mol Cell Endocrinol,2009

3. The biology of incretin hormones;Drucker;Cell Metab,2006

4. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits;Drucker;Diabetes Care,2010

5. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action;Hare;Diabetes,2010

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omarigliptin/rosinidin combination ameliorates cyclophosphamide-induced lung toxicity in rats: The interaction between glucagon-like peptide-1, TXNIP/NLRP3 inflammasome signaling, and PI3K/Akt/FoxO1 axis;Biomedicine & Pharmacotherapy;2024-08

2. Biotransformation and disposition characteristics of HSK7653, a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes;Diabetes, Obesity and Metabolism;2024-04-22

3. Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals;Metabolic Syndrome and Related Disorders;2024-03-01

4. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis;Endocrinology and Metabolism;2024-02-29

5. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis;Endocrinology and Metabolism;2024-02-29